TY - JOUR
T1 - Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer
AU - Ulahannan, Susanna V.
AU - Brahmer, Julie R.
PY - 2011/5
Y1 - 2011/5
N2 - Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
AB - Most patients with non-small cell lung cancer (NSCLC) present with advanced disease requiring systemic chemotherapy. Treatment with the antiangiogenic agent bevacizumab in combination with standard platinum-based doublet chemotherapy has been shown to improve outcomes in patients with advanced NSCLC. Several multitargeted antiangiogenic tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, and axitinib) are also being evaluated in combination with standard chemotherapy. Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC.
KW - Antiangiogenesis inhibitors
KW - Bevacizumab
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=79953793443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953793443&partnerID=8YFLogxK
U2 - 10.3109/07357907.2011.554476
DO - 10.3109/07357907.2011.554476
M3 - Review article
C2 - 21469981
AN - SCOPUS:79953793443
SN - 0735-7907
VL - 29
SP - 325
EP - 337
JO - Cancer Investigation
JF - Cancer Investigation
IS - 4
ER -